IP Library › Patent Application 16204076
Patent Application
App. No. 16/204,076

Treatment of Neurodegeneration and Neuroinflammation

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/204,076
Abstract

Methods of treating a subject having a condition characterized by at least one of neurodegeneration and neuroin-flammation are provided. Methods of reducing astrogliosis in a subject having a condition characterized by increased astrogliosis are also provided. Methods of providing neuroprotection to a subject in need thereof are also provided.

Claims (14)

1 - 40 . (canceled)

41 . A method of treating a subject having Friedreich ataxia, the method comprising administering to the subject a therapeutically effective amount of at least one compound of Formula I:

wherein R 1 and R 2 are independently selected from OH, O − , and (C 1-6 )alkoxy, provided that at least one of R 1 and R 2 is (C 1-6 )alkoxy, or a pharmaceutically acceptable salt thereof.

42 . The method of claim 41 , wherein the at least one compound is chosen from dimethyl fumarate and monomethyl fumarate.

43 . The method of claim 41 , wherein the only active agent administered to the subject is dimethyl fumarate.

44 . The method of claim 41 , wherein the only active agent administered to the subject is monomethyl fumarate.

45 . The method of claim 41 , wherein the only active agents administered to the subject are dimethyl fumarate and monomethyl fumarate.

46 . The method of claim 41 , wherein the at least one compound is administered orally.

47 . The method of claim 42 , wherein the at least one compound is administered orally.

48 . The method of claim 43 , wherein the at least one compound is administered orally.

49 . The method of claim 44 , wherein the at least one compound is administered orally.

50 . The method of claim 45 , wherein the at least one compound is administered orally.

51 . The method of claim 46 , wherein the at least one compound is administered in the form of a pill, a tablet, a microtablet, a pellet, a micropellet, a capsule, a capsule containing microtablets, or a liquid formulation.

52 . The method of claim 48 , wherein dimethyl fumarate is administered in the form of a capsule containing enteric coated microtablets.

Assignments (1)
CHANGE OF ASSIGNEE ADDRESS Recorded Feb 1, 2019
From: BIOGEN MA INC.
To: BIOGEN MA INC.
Reel/Frame 048226/0267 →